• About
• Links
• Contact
• Sitemap

The World Sleep Disorders Market, 2005-2010

The sleep disorder treatment market had sales of $2.03bn in 2004. It is dominated by one product, Ambien indicated for the short-term treatment of insomnia and providing Sanofi-Aventis with an 87% market share. However, in 2006 Ambien loses its patent protection, and the sleep disorder market looks set for dramatic growth and the introduction of at least four new products. In April 2005 year the first real competition for Ambien arrived on the market in the form of Estorra from Sepracor.

The purpose of this market report is to examine the factors that will influence the market and examine why visiongain has a forecast for the market to grow to over $4.4 billion by 2010. The imminent pipeline products are examined in detail and their potential strengths and weaknesses compared. The futures of the older products are assessed. Non-product related factors are considered as the insomnia treatment market has attracted considerable negativity associated with poor side effects and in particular dependency.

The potential for market growth is enormous with only 10% of the estimated potential patient population of 150 million using prescribed pharmaceutical products for insomnia. Although insomnia is by far the most common sleep disorder, this report also considers the markets for:

• Narcolepsy
• Restless Leg Syndrome (RLS)
• Obstructive Sleep Apnea (OSA).

Sanofi-Aventis is the leading company in the sleep disorder market, but over 25 companies are mentioned in this report. The report assesses which companies and products will be key companies by 2010.

Why you should buy this report

• It is a market that will more than double in size by 2010.
• It is a market that will change from one dominant product to one with at least 5 key products.
• Characteristics of an ideal sleep disorder treatment are compared with the current and pipeline products.
• Ambien is key product for Sanofi-Aventis and is at a pivotal point in its life cycle. How this will affect the future sales levels for Sanofi-Aventis is assessed.
• Sanofi-Aventis and Sepracor have significantly increased their level of DTC advertising. The importance of this and other non-product related factors are considered.

For anyone with or considering involvement with the sleep disorder market this report is the most recently published report to examine and consider all of the salient factors.

Table of Contents

• 1. Executive Summary
  • 1.1 World Sleep Disorder Market Set for an 62% Increase Between 2005 and 2010
  • 1.2 Aims, Scope and Format of this Report
• 2. Introduction
  • 2.1 Sleep Disorder Definitions
  
  
• 3. Disease Overview - What is a Sleep Disorder
  • 3.1 Sleep Disorders
  • 3.2 Insomnia
    • 3.2.1 Causes of Insomnia.
  • 3.3 Narcolepsy
    • 3.3.1 Causes of Narcolepsy
  • 3.4 Restless Leg Syndrome
    • 3.4.1 Causes of RLS
  • 3.5 Sleep Apnea
    • 3.5.1 Causes of Sleep Apnea
  • 3.6 The Different Stages of Sleep
  • 3.7 Treatments for Insomnia
  • 3.8 Ambien's Efficacy Explains its Dominance
  • 3.9 Myslee - Ambien for the Japanese market
  • 3.10 Sonata - Niche Market Status
  • 3.11 Imovane a Low Value Insomnia Product
  • 3.12 Benzodiazepines are Low Price Sleeping Agents
  • 3.13 Estorra - Ambien's First Real Competitor
  • 3.13 Treatments for Narcolepsy
  • 3.14 Provigil is the Leading Narcoleptic Treatment
  • 3.15 Ritalin is Also used for Daytime Sleepiness
  • 3.16 Adderall is Amphetamine Based
  • 3.17 Xyrem is GHB
  • 3.18 Anafranil is also Indicated for OCB
  • 3.19 Adrafinil is an Isomer of Provigil
  • 3.20 Treatment for Restless Leg Syndrome
  • 3.21 ReQuip is the Only Treatment for RLS
  • 3.22 Noctamid is the Only Treatment of OSA
  
  
  
• 4. World Market Overview for Insomnia - Forecast 2003-2010
  • 4.1 Ambien Dominates Market, but for How Much Longer?
  • 4.2 Current Competition For Ambien is Almost Non-Existent
  • 4.3 To What Extent Will Generic Competition Impact the Market?
  • 4.4 Branded competition, New Products, New Modes of Action
    • 4.4.1 Estorra
    • 4.4.2 Indoplon
    • 4.4.3 Rozerem
    • 4.4.4 Gaboxadol
    • 4.4.5 Posidorm
  • 4.5 Early and Mid-Stage Pipeline Products
  • 4.6 Concern Over Side Effects - Fact or Fiction?
  • 4.7 Characteristics of the Ideal Pharmaceutical Treatment for Insomnia
  • 4.8 Are these Needs Being Met?
  • 4.9 Non Product Related Drivers and Restraints
  • 4.10 Strengths and Weaknesses of Insomnia Treatments
  • 4.11 Summary Analysis
  
  
• 5. World Sleep Disorder Market by Country Region
  • 5.1 Is the US Not Sleeping?
  • 5.2 Will Europe Buy into the Market?
  • 5.3 The Japanese Market is Catching Up
  
  
• 6. World Market Overview for Other Sleep Disorders
  • 6.1 Narcolepsy - Old Products for New Markets
  • 6.2 Restless Leg Syndrome
  • 6.3 Sleep Apnea - There is An Alternative to Devices and Surgery
  • 6.4 Non Product Related Drivers and Restraints
  • 6.5 Summary Analysis
  
  
• 7. Sanofi-Aventis: A Review
  • 7.1 The Takeover of Aventis by Sanofi was Aggressive
  • 7.2 Sanofi-Aventis Continues to Expand
  
  
• 8. Conclusion: The Insomnia Market Will Show High Growth
  • 8.1 Other Sleep Disorders Acquire Limited Interest
  • 8.2 The Insomnia Market is Poised to Grow Significantly
    • 8.2.1 Life-Cycle Management by Sanofi-Aventis
    • 8.2.2 Branded Competition is Imminent
    • 8.2.3 Key pharmaceutical Companies Will Enter the Market with Vigour
    • 8.2.4 The Potential Patient Population is Huge

List Of Tables

Table 2.1 Sleep Disorder Definitions, 2005

Table 3.1 Currently Approved Insomnia Drugs, 2005

Table 3.2 World Sales ($m) for Insomnia Drugs, 2004

Table 3.3 Major Clinical Aspects of Insomnia Drugs, 2005

Table 3.4 Currently Approved Narcolepsy Drugs, 2005

Table 3.5 World Sales ($m) for Narcolepsy Drugs, 2004

Table 3.6 Currently Approved RLS Drugs, 2005

Table 3.7 Currently Approved OSA Drugs, 2005

Table 4.1 World Sales ($m) for Insomnia Drugs, 2003-2010

Table 4.2 World Market Share (%) of Insomnia Drugs, 2004

Table 4.3 World Sales ($m) for Imovane and Sonata, 2003-2010

Table 4.4 World Sales ($m) for Ambien, 2003-2010

Table 4.5 World Sales ($m) for Myslee, 2003-2010

Table 4.6 World Sales ($m) for Estorra, 2003-2010

Table 4.7 World Sales ($m) for Indoplon, 2003-2010

Table 4.8 World Sales ($m) for Rozerem, 2003-2010

Table 4.9 World Sales ($m) for Gaboxadol, 2003-2010

Table 4.10 World Sales ($m) for Posidorm, 2003-2010

Table 4.11 Pipeline Products for Insomnia, 2005

Table 4.12 Summary of Strengths and Weaknesses of Insomnia Drugs

Table 5.1 Potential Insomnia Patient Populations of the Major Pharmaceutical Markets, 2004

Table 6.1 World Sales ($m) for Narcolepsy Drugs, 2004

Table 6.2 World Sales ($m) for Narcolepsy Drugs, 2003-2010

Table 6.3 Approved Drugs for RLS, 2005

Table 6.4 Approved Drugs for OSA, 2005

Table 6.5 World Sales ($m) for Noctamid, 2003-2010

Table 7.1 World Drug Sales in 2003 for Aventis and Sanofi-Synthelabo Prior to the Takeover

Table 7.2 World Drug Sales for the Leading Sanofi-Aventis Prescription Drugs, 2004

Table 7.3 Sanofi-Aventis Sales ($m) by Originator Company, 2004

Table 7.4 World Sales ($bn) of All Leading Drugs of Pfizer, GSK and Samofi-Aventis, 2003-2004

List of Graphs

Graph 1.1 World Sales ($m) for Insomnia Drugs, 2004

Graph 4.1 World Sales ($bn) for All Insomnia Drugs, 2003-2010

Graph 4.2 World Sales ($m) for Main Insomnia Drugs, 2003-2010

Graph 4.3 World Sales ($m) for Sonata, 2003-2010

Graph 4.4 World Sales ($m) for Imovane, 2003-2010

Graph 4.5 World Sales ($m) for Ambien, 2003-2010

Graph 4.6 World Sales ($m) for Myslee, 2003-2010

Graph 4.7 World Sales ($m) for Estorra, 2003-2010

Graph 4.8 World Sales ($m) for Indoplon, 2003-2010

Graph 4.9 World Sales ($m) for Rozerem, 2003-2010

Graph 4.10 World Sales ($m) for Gaboxadol, 2003-2010

Graph 4.11 World Sales ($m) for Posidorm, 2003-2010

Graph 4.12 World Sales ($m) for all Insomnia Drugs, 2003- 2010

Graph 6.1 World Sales ($m) for Non-Insomnia Sleep Disorder Drugs, 2003-2010

List of Figures

Fig 4.1 World Market Share (%) for Insomnia Drugs, 2004

Fig 4.2 Market Share (%) for Insomnia Drugs, 2006

Fig 4.3 World Company Market Share (%), 2004

Fig 4.4 World Company Market Share (%), 2010

Fig 4.5 Market Share (%) for Insomnia Drugs 2010

Fig 5.1 Insomnia Drug Market Share (%) by Country, 2004

Fig 8.1 World Sales ($bn) of the Insomnia Drug Market, 2003-2010

Other users found this report page using the following search terms: sleep disorders insomnia RLS restless leg syndrome market sleep insomnia disorders disorder graphs sleeping size graph drugs

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.